AstraZeneca (NYSE:AZN) and GlaxoSmithKline (NYSE:GSK) have a lot of work ahead. Both are struggling to find revenue to replace sales from aging blockbusters (Nexium and Crestor for AstraZeneca and Advair for GlaxoSmithKline), although both also have some exciting pipeline prospects that may cushion that blow. Both also pay strong dividends, which may make them an intriguing play for income investors.

So, when comparing the two British pharmas, which is the better buy?

In the video below, Motley Fool health care analysts Michael Douglass and David Williamson answer.